LUCD Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 apr 2024 @ 22:00):

Stats
Dagens volum	275 028
Gjennomsnittsvolum	174 998
Markedsverdi	36.22M
EPS	$-0.250 ( 2024-03-26 )
Neste inntjeningsdato	( $-0.270 ) 2024-06-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.600
ATR14	$0.00500 (0.67%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-22	White Debra	Buy	150 000	Employee stock option (right to buy)
2024-02-22	Sparks Ronald M	Buy	150 000	Employee stock option (right to buy)
2024-02-22	Lapidus Stanley	Buy	150 000	Employee stock option (right to buy)
2024-02-22	Cox James L	Buy	150 000	Employee stock option (right to buy)
2024-02-22	Sokolov Jacque J	Buy	150 000	Employee stock option (right to buy)

INSIDER POWER
33.30
Last 57 transactions
Buy: 13 183 319 \| Sell: 4 158 892

Volum Korrelasjon

Lang: 0.04 (neutral)

Kort: -0.53 (weak negative)

Signal:(59.269) Neutral

Lucid Diagnostics Inc. Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Lucid Diagnostics Inc. Korrelasjon - Valuta/Råvare

0.33
( neutral )

-0.58
( weak negative )

0.00
( neutral )

0.86
( strong )

0.47
( neutral )

Lucid Diagnostics Inc. Økonomi

Annual	2023
Omsetning:	$2.43M
Bruttogevinst:	$-6.05M (-249.18 %)
EPS:	$-1.260

FY	2023
Omsetning:	$2.43M
Bruttogevinst:	$-6.05M (-249.18 %)
EPS:	$-1.260

FY	2022
Omsetning:	$377 000
Bruttogevinst:	$-3.24M (-858.62 %)
EPS:	$-1.550

FY	2021
Omsetning:	$500 000
Bruttogevinst:	$-85 000.00 (-17.00 %)
EPS:	$-1.510

Financial Reports:

No articles found.

Lucid Diagnostics Inc.

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.